Evan Dellon
University of North Carolina School of Medicine
Appearances
- DateMay 6, 2023The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed…
Presenter
University of North Carolina School of Medicine - DateMay 6, 2023The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed…
Presenters
ChildrenNorthwestern University - The Feinberg School of MedicineThe Children's Hospital of PhiladelphiaUniversity of North Carolina School of Medicine - DateMay 6, 2023SOCIETY: AGA
Presenters
EoE-Clinic, Olten, SwitzerlandNorthwestern University - The Feinberg School of MedicineUniversity of UtahUniversity of North Carolina School of MedicineUniversity of Colorado School of Medicine - DateMay 7, 2023This 90 minute session is designed to link junior faculty/GI fellows/other trainees who are interested in pursuing a clinical/research career in diseases of the upper gastrointestinal tract with established clinician/researcher experts in the field…
Presenters
University of North Carolina School of MedicineNorthwestern University - The Feinberg School of Medicine - DateMay 7, 2023This 90 minute session is designed to link junior faculty/GI fellows/other trainees who are interested in pursuing a clinical/research career in diseases of the upper gastrointestinal tract with established clinician/researcher experts in the field…
Presenters
University of ColoradoBaylor University Medical Center and Baylor Scott and White Research InstituteUniversity of North Carolina School of MedicineNorthwestern University - The Feinberg School of MedicineUniversity of California San DiegoVanderbilt Univ Medical CenterMayo ClinicSikKids HospitalVanderbilt University Medical Center - DateMay 8, 2023This session presents the best submitted clinical abstracts as determined by their specific council sections…
Presenter
Speakers
University of North Carolina School of Medicine - DateMay 8, 2023BACKGROUND: Tools predicting incident esophageal adenocarcinoma (EAC) and gastric cardia adenocarcinoma (GCA) that can be automated in electronic health records (EHRs) to guide screening decisions are needed…
Speakers
Presenter
University of North Carolina School of Medicine - DateMay 9, 2023SOCIETY: AGA
Moderators
University of North Carolina School of MedicineChildren - DateMay 7, 2023BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Presenter
University of North Carolina School of MedicineSpeakers
University of UtahUniversity of North Carolina at Chapel Hill School of Medicine - DateMay 7, 2023BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Presenter
University of North Carolina School of MedicineSpeakers
University of UtahUniversity of North Carolina at Chapel Hill School of Medicine - DateMay 7, 2023BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Presenters
Speakers
Kaiser PermanenteUniversity of North Carolina School of MedicineAmsterdam UMC, University of AmsterdamMount Sinai School of MedicineNorthwestern University - The Feinberg School of Medicine - DateMay 7, 2023BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Presenter
Amsterdam UMC, University of AmsterdamSpeakers
University of North Carolina School of Medicine - DateMay 7, 2023BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Presenter
Speakers
ChildrenUniversity of North Carolina School of Medicine - DateMay 9, 2023A family history of gastric cancer (GC) is a risk factor for developing this malignancy and portends an increased risk of precursor lesions such as gastric intestinal metaplasia (GIM)…
Presenter
Speakers
University of North Carolina School of Medicine - DateMay 9, 2023BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…
Presenter
Amsterdam UMC, University of AmsterdamSpeakers
University of North Carolina School of Medicine - DateMay 19, 2024
Presenter
University of North Carolina School of Medicine - DateMay 19, 2024
Presenters
ChildrenUniversity of North Carolina School of Medicine - DateMay 20, 2024BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
Presenter
University of North Carolina School of Medicine - DateMay 18, 2024BACKGROUND: Untreated eosinophilic esophagitis (EoE) can result in development of fibrostenosis over time, but there are few data on whether successful treatment in childhood decreases this risk as children with EoE transition to adulthood…
Presenter
Speakers
- DateMay 21, 2024BACKGROUND: Eosinophil infiltration is a hallmark of eosinophilic esophagitis (EoE). Histologic assessment of esophageal biopsies is required for diagnosis and evaluation of treatment effect. Current diagnostic criteria are based mainly upon a peak eosinophil count (PEC) ≥15…
Presenter
Speakers
Amsterdam UMC, University of AmsterdamUniversity of North Carolina School of MedicineWestern UniversityWestern University - DateMay 21, 2024Interleukin-15 (IL-15) is a cytokine involved in tissue homeostasis and inflammation, and a potent regulator of innate and adaptive immune responses. IL-15 expression has been shown to be dysregulated in eosinophilic esophagitis (EoE)…
Presenter
Amsterdam UMC, University of AmsterdamSpeakers
University of North Carolina School of Medicine - DateMay 21, 2024Esophageal eosinophilic inflammation and remodeling lead to fibrostenosis in many patients with eosinophilic esophagitis (EoE)…
Presenter
University of North Carolina School of Medicine - DateMay 21, 2024The goals of treatment of eosinophilic esophagitis (EoE) are to improve clinical symptoms and histologic features, as well as prevent progression to fibrostenotic complications. Few data currently exist that evaluate the effectiveness of therapies as measured by complete resolution of symptoms…
Presenter
University of North Carolina School of Medicine - DateMay 21, 2024BACKGROUND: Dietary therapy is an effective treatment for eosinophilic esophagitis (EoE), however, the influence of body mass index (BMI) on treatment response is unclear…
Presenter
Speakers
- DateMay 21, 2024
Presenters
University of North Carolina School of MedicineNorthwestern University - The Feinberg School of Medicine